# To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM

Study · id `cardio:ct-nct05814406` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05814406](<https://clinicaltrials.gov/study/NCT05814406>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05814406

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

## Technical summary

Registry record NCT05814406. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-12 (actual); primary completion 2024-03-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 196 participants (enrolled count; ClinicalTrials.gov record NCT05814406, source copy `cardio:ctgov-nct05814406-2025-09-09`, retrieved 2026-10-26)
- Started: 2023-01-12 (actual) (ClinicalTrials.gov record NCT05814406, source copy `cardio:ctgov-nct05814406-2025-09-09`, retrieved 2026-10-26)
- Primary completion: 2024-03-21 (actual) (ClinicalTrials.gov record NCT05814406, source copy `cardio:ctgov-nct05814406-2025-09-09`, retrieved 2026-10-26)
- Completion: 2024-03-21 (actual) (ClinicalTrials.gov record NCT05814406, source copy `cardio:ctgov-nct05814406-2025-09-09`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05814406, source copy `cardio:ctgov-nct05814406-2025-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05814406-2025-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): JW0201
- Intervention (Drug): Placebo
- Lead sponsor: JW Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: JW Pharmaceutical (`cardio:org-jw-pharmaceutical`)

## Provenance

Content hash: e7e3cb22465c99ad1222292dd3f7c595b42b0262fb878db1510e834b5a6ed09f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
